Collegium Pharmaceutical
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 months.
- Its last 5 Sell calls were followed by roughly flat moves (+1%) three months out.
- Recent price momentum is -27.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 16.8% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 22.7x | Better than 35% |
| Forward P/E | 12.6x | Better than 65% |
| Price / Sales | 1.0x | Better than 78% |
| P/E vs own 5-yr range | 74th pctl | Better than 34% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 18.9% | Better than 81% |
| Net income CAGR (3Y) | -1.1% | Better than 39% |
| Free cash flow CAGR (3Y) | 38.8% | Better than 80% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 59.3% | Better than 73% |
| Operating margin | 22.9% | Better than 81% |
| Net margin | 8.1% | Better than 54% |
| Return on equity | 23.7% | Better than 82% |
| Return on invested capital | 10.1% | Better than 68% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -8.8% | Better than 53% |
| 6-month return | -27.4% | Better than 20% |
| 12-month return (ex latest month) | -49.1% | Better than 3% |
| Distance below 52-week high | 51.3% | Better than 17% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.6x | Better than 43% |
| Debt to assets | 49.2% | Better than 16% |
| Interest coverage | 2.1x | Better than 37% |
| Free cash flow / net income | 521.0% | Better than 93% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 84.1% | Better than 79% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 25.21
- Open
- 25.06
- Day range
- 24.64 - 25.43
- Avg price
- 24.85
- Volume
- 528.02K
- Turnover
- 13.12M
- Turnover ratei
- 1.87%
- Volume ratioi
- 1.20
- Amplitudei
- 3.15%
- 52-week rangei
- 21.43 - 50.79
Valuation
- P/Ei
- 14.29
- P/E (TTM)i
- 22.68
- P/Bi
- 2.59
- EPSi
- 1.73
- Book value / shi
- 9.54
- Net profit
- 53.76M
- Net assets
- 296.43M
Share structure
- Market cap
- 768.18M
- Float capi
- 698.96M
- Shares out
- 31.08M
- Float sharesi
- 28.27M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-05-07
51.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-419.74K net over the window
Short interest
- Shares short
- 5.19M
- % of floati
- 16.76%
- Days to coveri
- 9.40
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Collegium Pharmaceutical (COLL)?
Collegium Pharmaceutical last traded at 24.72. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Collegium Pharmaceutical's market cap?
About 768.18M.
What is the P/E ratio of Collegium Pharmaceutical?
The trailing twelve-month P/E is 22.68, above its own 5-year average of 11.57 — toward the top of its historical range (73.66% percentile). See the Valuation tab for the full history.
Does Collegium Pharmaceutical pay a dividend?
Collegium Pharmaceutical does not currently pay a regular dividend.
Is Collegium Pharmaceutical a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 45.50, which implies 84.1% upside from the current price. This is not investment advice.
What is Collegium Pharmaceutical's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Collegium Pharmaceutical a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Collegium Pharmaceutical discussion 0 comments